The global cardiac safety services market size is anticipated to reach USD 1.92 billion by 2030 and is projected to grow at a CAGR of 12.0% from 2024 to 20230. This growth is driven by the alarming prevalence of cardiovascular diseases (CVDs) and significant advancements in medical technology. As per the CDC, in U.S., one person dies due to any cardiovascular disease every 33 seconds, underscoring the critical need for effective cardiac monitoring and intervention. In 2022, heart disease caused 702,880 deaths, representing one in every five deaths and highlighting the vast market potential for cardiac safety services.
Moreover, approximately 805,000 people in the U.S. experience a heart attack each year, with 605,000 being first-time incidents and 200,000 involving individuals who have previously suffered a heart attack. Expanding clinical trials, particularly those focused on cardiovascular diseases or involving therapies with potential cardiovascular impacts, drives the demand for cardiac safety services. As pharmaceutical and biopharmaceutical companies invest in developing new cardiovascular drugs and devices, there is an increased need for specialized cardiac safety assessments to ensure that these products do not adversely affect heart health. This growth in clinical trials, combined with the complexity of modern trials, necessitates robust and reliable cardiac safety services to support drug development and regulatory compliance.
Pharmaceutical companies, medical device manufacturers, and academic institutions continually invest in R&D to drive innovation and growth in the cardiac safety services market. Research initiatives often require sophisticated cardiac safety monitoring to support the development of new therapies and technologies. This investment fosters the development of new cardiac safety solutions and supports continuously improving existing services.
This product will be delivered within 2 business days.
Moreover, approximately 805,000 people in the U.S. experience a heart attack each year, with 605,000 being first-time incidents and 200,000 involving individuals who have previously suffered a heart attack. Expanding clinical trials, particularly those focused on cardiovascular diseases or involving therapies with potential cardiovascular impacts, drives the demand for cardiac safety services. As pharmaceutical and biopharmaceutical companies invest in developing new cardiovascular drugs and devices, there is an increased need for specialized cardiac safety assessments to ensure that these products do not adversely affect heart health. This growth in clinical trials, combined with the complexity of modern trials, necessitates robust and reliable cardiac safety services to support drug development and regulatory compliance.
Pharmaceutical companies, medical device manufacturers, and academic institutions continually invest in R&D to drive innovation and growth in the cardiac safety services market. Research initiatives often require sophisticated cardiac safety monitoring to support the development of new therapies and technologies. This investment fosters the development of new cardiac safety solutions and supports continuously improving existing services.
Cardiac Safety Services Market Report Highlights
- Based on service, the ECG/Holter monitors segment led the market with the largest revenue share of 41.0% in 2023. Electrocardiogram (ECG) and Holter monitors are crucial tools for continuous cardiac monitoring, enabling real-time detection of arrhythmias, ischemic episodes, and other cardiovascular conditions
- Based on type, the integrated segment led the market with the largest revenue share of 63.17% in 2023. This prominence is primarily driven by the increasing demand for comprehensive, multi-functional cardiac monitoring solutions that offer enhanced accuracy, efficiency, and patient convenience
- Based on end use, the pharma & biopharma segment led the market with the largest revenue share of 44.2% in 2023
The leading players in the Cardiac Safety Services market include:
- Medpace
- IQVIA
- PPD Inc.,
- Charles River Laboratories
- Wuxi AppTec
- Eurofins Scientific
- Celerion
- Nova Research Laboratories
- Laboratory Corporation of America Holdings
- Koninklije Philips N.V.
- ICON Plc.
- SGS S.A.
- Clario
- Certara
- Richmond Pharmacology
- Biotrial
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Cardiac Safety Services Market Variables, Trends & Scope
Chapter 4. Cardiac Safety Services Market: Service Estimates & Trend Analysis
Chapter 5. Cardiac Safety Services Market: Type Estimates & Trend Analysis
Chapter 6. Cardiac Safety Services Market: End Use Estimates & Trend Analysis
Chapter 7. Cardiac Safety Services Market: Regional Estimates & Trend Analysis by Treatment, Type, and End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the Cardiac Safety Services market include:- Medpace
- IQVIA
- PPD Inc.,
- Charles River Laboratories
- Wuxi AppTec
- Eurofins Scientific
- Celerion
- Nova Research Laboratories
- Laboratory Corporation of America Holdings
- Koninklije Philips N.V.
- ICON Plc.
- SGS S.A.
- Clario
- Certara
- Richmond Pharmacology
- Biotrial
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 870.48 Million |
| Forecasted Market Value ( USD | $ 1920 Million |
| Compound Annual Growth Rate | 12.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
